Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339415 · ClinicalTrials.gov registry record · Phase 2
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
A Phase 2 study, sponsored by Hennepin Healthcare Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT02339415: Completed Phase 2 study, sponsored by Hennepin Healthcare Research Institute.
NCT02339415 is a Phase 2 study that has completed, run by Hennepin Healthcare Research Institute. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02339415, a Phase 2 study, has completed, sponsored by Hennepin Healthcare Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
Primary Outcome
Difference between treatment and control ln-transformed IL-6 plasma levels in change from pre-treatment to on-treatment values
Interventions
- DRUG Matching placebo
- DRUG Edoxaban 30mg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-07 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
What the finished NCT02339415 record still lists
NCT02339415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 2 interventions - of which Matching placebo is the first listed.
NCT02339415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02339415 about?
NCT02339415 is a clinical study titled "Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease". The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
What is the current status of trial NCT02339415?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2015-07. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02339415?
The interventions under investigation include: Matching placebo (DRUG), Edoxaban 30mg daily (DRUG).
Who is sponsoring clinical trial NCT02339415?
This trial is sponsored by Hennepin Healthcare Research Institute, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02339415's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia